bupivacaine pamoate microparticle suspension (HYR-PB21) / Hefei Cosource - LARVOL DELTA

To evaluate the efficacy and safety of HYR-PB21 for injection in patients undergoing unilateral hallux valgus osteotomy, a randomized, double-blind, positive-drug and placebo-controlled, multicenter phase III clinical trial protocol (ChiCTR) - P3 | N=300 | Not yet recruiting | Sponsor: Beijing Tongren Hospital, Capital Medical University; Hefei cosource Pharmaceutical Co. LTD

New P3 trial • Orthopedics

To evaluate the efficacy and safety of HYR-PB21 for injection for postoperative analgesia in patients undergoing unilateral hallux valgus osteotomy (ChiCTR) - P2 | N=72 | Not yet recruiting | Sponsor: Beijing Tongren Hospital, Capital Medical University; Hefei Cosource Pharmaceutical Inc

New P2 trial • Orthopedics

Local infiltration of HYR-PB21, a sustained-release formulation of bupivacaine, provides analgesia and reduces opioid requirement after haemorrhoidectomy: a randomised controlled trial. (PubMed, Br J Anaesth) - "Local infiltration of a single dose of HYR-PB21 sustained-release bupivacaine had better efficacy in controlling postoperative pain, with similar adverse effects, compared with a single dose of bupivacaine HCl in patients after haemorrhoidectomy."

Journal • Anesthesia • Pain

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of HYR-PB21 in Healthy Volunteers (clinicaltrials.gov) - P1; N=32; Completed; Sponsor: Fruithy Medical Pty Ltd; Recruiting ➔ Completed

Clinical • Trial completion • Pain